+

WO1999008710A1 - BIOTHERAPIE DU CANCER PAR CIBLAGE TP-3/p80 - Google Patents

BIOTHERAPIE DU CANCER PAR CIBLAGE TP-3/p80 Download PDF

Info

Publication number
WO1999008710A1
WO1999008710A1 PCT/US1997/014439 US9714439W WO9908710A1 WO 1999008710 A1 WO1999008710 A1 WO 1999008710A1 US 9714439 W US9714439 W US 9714439W WO 9908710 A1 WO9908710 A1 WO 9908710A1
Authority
WO
WIPO (PCT)
Prior art keywords
pap
antibody
osteosarcoma
agent
cancer
Prior art date
Application number
PCT/US1997/014439
Other languages
English (en)
Inventor
Fatih Uckun
Peter M. Anderson
Original Assignee
Regents Of The University Of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regents Of The University Of Minnesota filed Critical Regents Of The University Of Minnesota
Priority to AU39163/97A priority Critical patent/AU3916397A/en
Priority to PCT/US1997/014439 priority patent/WO1999008710A1/fr
Publication of WO1999008710A1 publication Critical patent/WO1999008710A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin

Definitions

  • adjuvant chemotherapy is a standard treatment approach for many sarcomas including Ewing's sarcoma, rhabdomyosarcoma, and osteosarcoma.
  • Bass et al. "General Principals of Chemotherapy", In: Principles and Practice of Pediatric Oncology, 2nd ed., Pizzo et al. eds., J.B. Lippincott Company, Philadelphia, pp. 197-245 (1993). It has been more difficult, however, to demonstrate significant benefit of chemotherapy in adult soft tissue sarcomas and osteosarcoma with metastatic disease at diagnosis or after the development of lung metastases.
  • Elias et al. "Adjuvant chemotherapy for soft tissue sarcoma: an approach in search of an effective regimen", Seminars in
  • MoAbs or other cell targeting proteins are linked to cytotoxic agents to form molecules referred to as biotherapeutics which potentially combine the selectivity of the carrier moiety (e.g., MoAb) with the potency of the cytotoxic moiety.
  • the choice of carrier moiety can be based on the surface antigen profile of a given malignant cell determined by reaction with an enzyme or fluorescently labelled antibody.
  • biotherapeutics have been under investigation for the treatment of various cancers, and more recently, for the treatment of immunological disorders such as rheumatoid arthritis and acquired immune deficiency syndrome (AIDS). Although these agents have shown some potential to provide safe and effective therapy for certain human pathologies, many difficulties remain. Ideally, consistently locatable and reliable markers on target cells would permit the binding portion of biotherapeutics to completely avoid binding to non-target tissue. In reality, cross-reactivity with antigens expressed by vital organs often gives rise to unacceptable complications in in vivo applications. There is also the potential that a patient will demonstrate immune responses to the separate components of the biotherapeutic agent, especially if they are not natural human proteins, even though the patient may already be immunosuppressed by the course of their disease.
  • the present invention provides cytotoxic biotherapeutic agents which comprise a toxin, preferably pokeweed antiviral protein (PAP), linked to a carrier, preferably an antibody or antibody fragment which binds to the p80 cell surface receptor.
  • PAP pokeweed antiviral protein
  • the p80 antigen is associated with the tumor cells as well as tumor blood vessels of cancers such as osteosarcoma or soft tissue sarcoma.
  • the toxin portion of the biotherapeutic agent acts to inhibit the division of, or to kill the target tumor cell without a significant non-specific toxicity (i.e., innocent bystander effect) on surrounding normal tissues that do not express the cell surface receptor for which the antibody is specific.
  • the biotherapeutic agent may kill the target tumor not only directly by exhibiting cytotoxicity to the individual tumor cells but also indirectly by killing the blood vessels responsible for carrying oxygen and nutrients to the tumor. Rapid necrosis of xenografted human osteosarcoma was observed in a SCID mouse model. Most importantly, survivial of SCID mice xenografted with human osteosarcoma was markedly improved upon treatment with TP-3-PAP, due to this particular biotherapeutic agent's prevention of tumor progression. The cytotoxicity exhibited by the bioactive agents of the present invention was unexpectedly potent, since neither unconjugated PAP nor unconjugated TP-3 inhibited tumor cell growth, even at much higher concentrations.
  • a preferred embodiment of the invention comprises a cytotoxic amount of a PAP molecule linked to a carrier such as a monoclonal antibody or antibody fragment which binds specifically to a receptor on a sarcoma cell.
  • preferred carriers are TP-1 and TP-3 as well as Fab or Fab 2 , which are active fragments of TP-3, and single chain FV (scFV) of TP-1 or TP-3, a recombinant antibody which recognizes the target antigen.
  • the carrier used will be TP-3 or it's active fragments Fab, Fab 2 or scFV.
  • the bioactive agent resulting from the conjugation of PAP and the preferred carrier can be designated TP-3-PAP.
  • the term "carrier” includes antibodies, antibody fragments and subunits thereof which are at least equivalent in their binding specificity.
  • a "cytotoxic amount” means that at least one, i.e., 1-3 molecules of PAP are linked to each antibody molecule.
  • the present invention also provides a therapeutic method for the treatment of target cancers.
  • the method comprises parenterally administering to a patient who is afflicted with a target cancer an effective amount of a pharmaceutical composition comprising a biotherapeutic agent consisting of monoclonal antibody TP-3 covalently linked to an effective cytotoxic amount of PAP, in combination with a pharmaceutically acceptable carrier.
  • a pharmaceutical composition comprising a biotherapeutic agent consisting of monoclonal antibody TP-3 covalently linked to an effective cytotoxic amount of PAP, in combination with a pharmaceutically acceptable carrier.
  • target cancer refers to diseases associated with the proliferation of mammalian cells expressing the antigen recognized by TP-1 and TP-3, i.e., the p80 antigen.
  • the p80 antigen may be expressed either on the tumor blood vessels or the tumor cells themselves of the target cancer.
  • target cancers include, but are not limited to, other human sarcomas including osteosarcoma, hemangiopericytoma, chondrosarcoma, malignant fibrous histiocytoma (MFH), Kaposi's sarcoma, fibrosarcoma and synovial cell sarcoma.
  • PAP refers to any cytotoxic pokeweed antiviral protein, or derivative thereof, including subtypes PAP-II and PAP-S.
  • the high cytotoxicity action of this immunotoxin was unexpected since neither PAP nor TP-3 alone was found to be cytotoxic at equivalent, or greater, concentration.
  • TP-3-PAP was found to be much more potent than PAP immunoconjugates directed against leukemia-associated antigens (e.g., B43- PAP).
  • a p80 directed biotherapeutic agent such as TP- 3-PAP, can inhibit the growth of sarcomas not onlv bv selectivelv destroving cancer cells but also the vascular endothelium of the tumor.
  • TP- 3-PAP a p80 directed biotherapeutic agent
  • TP- 3-PAP can inhibit the growth of sarcomas not onlv bv selectivelv destroving cancer cells but also the vascular endothelium of the tumor.
  • the destruction in such neovasculature results in the ultimate death of the tumor. Folkman et al., In: Biologic Therapy of Cancer, DeVita et al., eds., J.B. Lippincott Company, pp. 743-753 (1991).
  • the TP-3-PAP biotherapeutic agent may further aid the entry of antineoplastic agents by providing damage sites or "windows" in the tumor vasculature through which the antineoplastic agents may enter the tumor.
  • a further embodiment of the present invention comprises the administration of a biotherapeutic agent followed by administration of an effective amount of one or more conventional antineoplastic agents.
  • the antineoplastic agents employed are doxorubicin, methotrexate, etoposide, and alkylating agents such as the oxazaphosphorines (cyclophosphamide and ifosfamide) and platinum compounds such as cisplatin and carboplatin.
  • Figures 1A, IB and 1C depict the purification and characterization of TP-3- PAP.
  • Figure 1A is an HPLC elution profile which shows TP-3-PAP eluting at 38 min and free PAP eluting at 56 min
  • Figure IB is a Coomassie Blue stained gel of TP-3 and TP-3-PAP
  • Figure 1C is a Western Blot conducted with anti-PAP.
  • Figures 2A and 2B illustrate the proliferation of human OHS osteosarcoma cells after treatment with TP-3 MoAb, PAP, and TP-3-PAP immunotoxin as determined by a 3 H thymidine incorporation assay.
  • Figure 2A shows that TP-3-PAP, but not TP-3 MoAb alone inhibited growth of OHS cells
  • Figure 2B shows that the TP-3 binding moiety was necessary for PAP toxin's effect on OHS cells at low concentrations.
  • B43-PAP, an anti-CD19-PAP immunotoxin which does not bind CD19 negative OHS cells had minimal effects even at very high concentrations (>1000 pM).
  • Figures 3A and 3B depict the effect of TP-3-PAP on TP-3 negative cell lines.
  • Figure 3A shows the effect on a culture of canine D17 osteosarcoma of human serum albumin (HSA), TP-3 MoAb, TP-3-PAP immunotoxin or B43-PAP immunotoxin.
  • Figure 3B illustrates the effect of HSA, TP-3 MoAb, TP-3-PAP and B43-PAP on the CD19+ RS4;11 human ALL cell line.
  • Figure 4 is a bar graph that is illustrative of the dose response of TP-3-PAP immunotoxin against MCA106 sarcoma lung metastases.
  • Figure 5 depicts the effect of TP-3-PAP on the tumor volume of subcutaneous OHS (human osteosarcoma) after injection of the right hind limb of C.B.-17-SCID mice.
  • Figure 6 illustrates the tumor free survival of mice injected with subcutaneous human osteosarcoma (OHS) and subsequently treated with either PBS or TP-3-PAP.
  • OHS subcutaneous human osteosarcoma
  • Immunotoxins are a relatively new class of biotherapeutic agents that are prepared by covalently linking cell type- specific polyclonal or monoclonal antibodies to one of a variety of catalytic toxins either directly, as via a covalent bond, or via a linking agent.
  • Immunotoxins In the case of sarcoma, as discussed below, immunotoxin technology provides a potent means to achieve effective therapeutic use of the TP-3 and TP-1 MoAb.
  • Monoclonal antibodies are produced by the fusion of spleen lymphocytes with malignant cells (myelomas) of bone marrow primary tumors. Milstein, Sci. Am.. 243, 66 (1980). The procedure yields a hybrid cell line, arising from a single fused cell hybrid, or clone, which possesses characteristics of both the lymphocytes and myeloma cell lines. Like the lymphocytes (taken from animals primed with sheep red blood cells as antigens), the fused hybrids or hybridomas secrete antibodies (immunoglobulins) reactive with the antigen. Moreover, like the myeloma cell lines, the hybrid cell lines are immortal.
  • the single-type of immunoglobulin secreted by a hybridoma is specific to one and only one determinant on the antigen, a complex molecule having a multiplicity of antigenic molecular substructures, or determinants (epitopes).
  • monoclonal antibodies raised against a single antigen may be distinct from each other depending on the determinant that induced their formation.
  • all of the antibodies produced by a given clone are identical.
  • hybridoma cell lines can be reproduced indefinitely, are easily propagated in vitro and in vivo, and yield monoclonal antibodies in extremely high concentration.
  • Monoclonal antibodies TP-1 and TP-3 have been shown to react with different epitopes of an 80 kd antigen on human and canine osteosarcoma which is referred to as the p80 antigen.
  • Bruland, et al. "New monoclonal antibodies specific for human sarcomas", Int. T. Cancer, 38, 27 (1986).
  • TP-3 is an IgG 2 b monoclonal antibody which recognizes mesenchymal tumors including osteosarcomas as well as the budding capillaries of a wide variety of tumors. 0.
  • TP-1 and TP-3 also bind a variety of other human sarcomas including hemangiopericytoma, chondrosarcoma, malignant fibrous histiocytoma (MFH), and synovial cell sarcoma.
  • Bruland, et al. "Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen", Cancer Research.48, 5302 (1988).
  • the distribution of the TP-l/TP-3 antigen on normal tissues is very limited. This limited tissue distribution that makes the TP-3 antigen an attractive choice for immunotoxin therapy.
  • the current state of knowledge of distribution of the TP-l/TP-3 antigen on normal tissues and mesenchymal tumors has been recently summarized by Bruland and Phil.
  • Negative tissues included fibroblasts, peripheral blood cells, cells in the marrow, fetal skin fibroblasts, fetal lung fibroblasts, amnio cytes, fibrous connective tissue, skeletal muscle, cartilage, synovia, peripheral nerve, tonsil, spleen, liver, colon, and lung.
  • the variety of toxins that have been employed in immunotoxins by various investigators can be broadly categorized into two groups.
  • the first group consists of intact toxins, such as ricin.
  • Ricin consists of two subunits, the A chain which is capable of inactivating as many as 1,500 ribosomes per minute and the B chain which recognizes non-reducing terminal galactose residues on cell surfaces and facilitates A chain entry.
  • intact ricin immunotoxins are highly effective destroyers for their target cells, they cannot be applied for in vivo treatment of leukemia because of the nonselectability of their B chain moiety.
  • Hemitoxins are single-chain ribosome inactivating proteins that act catalytically on eukaryotic ribosomes and inactivate the 60-S subunit, resulting in an irreversible shut-down of cellular protein synthesis at the level of peptide elongation.
  • Such polypeptide toxins have been isolated from pokeweed (Phytolacca americ na), bitter gourd (Momordica charantia), wheat (Tritium vulgaris), soapwort (Saponaria officinalis), Gelonium multi ⁇ orum, and several other plants.
  • PAP pokeweed antiviral protein
  • PAP is a member of the hemitoxin group of toxins and thus inactivates ribosomes by the specific removal of a single adenine from the conserved loop sequence found near the 3' terminus of all larger rRNAs. Irvin et al., Pharmacology and Therapeutics. 55, 279, (1992). This specific depurination greatly reduces the capability of elongation factors to interact with ribosomes and results in an irreversible shut-down of protein synthesis. Irvin et al., cited supra. Furthermore, PAP is one of the most active ribosomal inactivating proteins.
  • the biotherapeutic agents of the present invention can generally be defined as compounds formed by linking cytotoxic agents, such as the toxins disclosed above, to carriers capable of delivering the cytotoxic agents to specific target cells or organs.
  • the biotherapeutic agents of the present invention can include not only immunotioxins as defined above, but also, constructs synthesized by known methods of genetic engineering, e.g., recombinant proteins.
  • the activity of these biotherapeutic agents depends not only on the toxin utilized, but also on efficient binding of antibody to antigen, endocytosis, and intracellular release of functional ribosome inactivating proteins.
  • TP-3-PAP is a biotherapeutic agent composed of monoclonal antibody TP-3, an IgG 2b monoclonal antibody which recognizes mesenchymal tumors, covalently coupled to the ribosome inhibitory plant toxin PAP. Since the potency of PAP is such that a few molecules in the cytoplasm are sufficient to kill a cell, TP-3 antigen density may be less important than specificity of binding in determining ultimate usefulness and therapeutic index of this particular immunotoxin. Vitetta et al., "Immunotoxins" In: Biologic Therapy of Cancer. V. T. DeVita, Jr., S. Hellman, S. A. Rosenberg (eds.), J. B. Lippincott Company, pp. 482-495 (1991). Furthermore, the unexpected potency of TP-3-PAP, which seems unique to this PAP immunotoxin, allows the administration of less immunotoxin to achieve a therapeutic benefit.
  • biotherapeutic agents are formed by linking an effective cytotoxic amount of PAP molecules to each molecule of TP-1 or TP-3.
  • a reagent useful in the practice of the invention is a mixture of TP-3- PAP having 1-3 PAP molecules per TP-3 molecule.
  • Heterobifunctional cross-linking reagents useful in the formation of monoclonal antibody-PAP immunotoxins include SPDP (N-succinimidyl 3- (2-pyridyldithio)propionate) and its derivatives.
  • SPDP N-succinimidyl 3- (2-pyridyldithio)propionate
  • the particular TP-3-PAP employed in the examples hereinbelow is prepared by modifying TP-3 MoAb with the crosslinking agent SPDP and then reacting the modified
  • biotherapeutic agents of the present invention can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient, in a variety of forms adapted to the chosen parenteral route of administration, i.e., by intravenous, intramuscular or subcutaneous routes. a. Dosage Forms
  • the biotherapeutic agents of the present invention be parenterally administered, i.e., intravenously, or subcutaneously by infusion or injection.
  • Solutions or suspensions of the biotherapeutic agent can be prepared in water, or isotonic saline, such as PBS, optionally mixed with a nontoxic surfactant.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMA, vegetable oils, triacetin, and mixtures thereof. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms. Because sarcomas often metastasize to the lungs, more specific delivery of the therapeutic agent to the lungs may be accomplished via aerosol delivery systems.
  • the pharmaceutical dosage form suitable for aerosol delivery can include adipot formulations such as a liposome of suitable size.
  • the pharmaceutical dosage form suitable for injection or infusion use can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions.
  • the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, lipids (for example, dimyristoyl phosphatidyl choline) and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersion or by the use of nontoxic surfactants.
  • the prevention of the action of microorganisms can be accomplished by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, buffers or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the inclusion in the compositions of agents delaying absorption, for example, aluminum monostearate hydrogels and gelatin.
  • Sterile injectable or infusable solutions are prepared by incorporating the biotherapeutic agents in the required amount in the appropriate solvent with various of the other ingredients enumerated above, and as required, followed by filter sterilization.
  • the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
  • the dosage of the biotherapeutic agents in said composition can be varied widely, in accord with the size, age and condition of the patient and the target cancer. Based on animal data, it is expected that the dosage can be varied between 0.025 mg/kg and 1 mg/kg, administered over a period of about 1 to 7 days..
  • OHS line is an adherent human osteosarcoma line with high constitutive expression of the TP1/3 antigen.
  • OHS was derived by Fostad et al. from an adolescent with metastatic osteosarcoma which occurred 13 years after retinoblastoma. ("Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma". Int. T. Cancer.38, 33 (1986)).
  • OHS was obtained from Dr. Deborah Haines (Western College of Veterinary Medicine, Saskatoon, Canada) and passaged in RPMI
  • D17 canine osteosarcoma was obtained from Dr. Stuart Helfand (University of Wisconsin, Madison WI); D17 is negative for TP-3 antigen.
  • Example 1 TP-3 MoAb production and purification.
  • TP-3 MoAb hybridoma was obtained by immunization of BALB/c mice against a human osteosarcoma xenograft as described by Fostad et al. ("Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma", Int. T. Cancer, 28, 33 (1986)). Briefly, TP-3 hybridoma cells were cultured in DMEM (Celox, Hopkins MN) containing 25 mM HEPES, 2 mM L-glutamine,
  • mice 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 10 mM nonessential amino acids, 100 mM sodium pyruvate, and 10% fetal calf serum (FCS; Sigma, St. Louis MO).
  • FCS fetal calf serum
  • BALB/c mice were primed with 0.5 ml pristane (Aldrich Chemical Co., Milwaukee WI) intraperitoneally (i.p.) 7 days before injection of 2 x 106 TP-3 hybridoma cells i.p. Ascites containing TP-3 MoAb was collected, centrifuged at 12,000g x 20 minutes, pooled, and filtered through a 0.22 ⁇ m filter.
  • TP-3 MoAb was further purified using ammonium sulfate precipitation and affinity chromatography with protein A agarose (Immunopure Plus immobilized protein A; Pierce, Rockford IL). Elution from Protein A was accomplished with Immunopure elution buffer (Pierce).
  • TP-3 was dialyzed against PBS and sterile filtered prior to use.
  • Example 2 TP-3-PAP immunotoxin synthesis.
  • TP-3 MoAb was purified as described in Example 1, above, while PAP was purified using spring leaves of pokeweed (Phytolacca americ na) as starting material as previously described by Irvin et al. ("Pokeweed antiviral protein: ribosome inactivation and therapeutic applications", Pharmac. Ther., 55, 279 (1992)).
  • TP-3 MoAb Purified TP-3 MoAb at a concentration of 8 mg/mL in PBS, was reacted with a 3.5:1 molar excess of SPDP (N-succinimidyl 3-(2- pyridyldithio)propionate (Pharmacia, Biotech Inc., Piscataway, NJ) which was freshly prepared in DMSO and diluted 1:10 in PBS immediately prior to use.
  • SPDP N-succinimidyl 3-(2- pyridyldithio)propionate
  • PAP purified and dialyzed against PBS, pH 8.0, was concentrated to 10 mg/mL and mixed with a 3.5:1 molar excess of 2-iminothiolane HCl (Pierce, Rockford, IL) which was prepared just prior to use in 50 mM sodium phosphate, pH 8.6. Both modification procedures were carried out for 1.5 hours at room temperature with gentle rocking in sterile and pyrogen-free glass vials.
  • TP-3-PAP The pH and conductivity of the dialyzed TP-3-PAP were adjusted to that of the CM- Sepharose resin, which was first equilibrated in 10 mM sodium phosphate pH 6.5.
  • the CM-Sepharose column was washed briefly with 10 mM sodium phosphate pH 7.1; TP-3 MoAb was eluted in 10 mM sodium phosphate, pH 7.8, containing 20 mM sodium chloride, and TP-3-PAP immunotoxin was recovered from the PBS, pH 7.5, eluant.
  • TP-3-PAP immunotoxin began to elute approximately 34 minutes after injection, followed closely by unreacted TP-3 MoAb. Free PAP eluted at 56 min and was well-separated from the immunotoxin.
  • the HPLC semi-purified material still contained significant amounts of unreacted TP-3 MoAb.
  • PAP primary antibody was generated in rabbits that had been hyperimmunized with highly purified PAP. Immunoblotting was also done using alkaline phosphatase-conjugated goat anti-mouse IgG (Sigma Chemical Co., St. Louis, MO) to detect unconjugated anti-TP-3 monoclonal antibody remaining in the purified immunoconjugate preparations, as previously reported by Myers et al., cited supra. Protein concentrations were determined using the Bicinchoninic Assay System obtained from Sigma.
  • Example 3 TP-3-PAP immunotoxin activity against human OHS osteosarcoma cells.
  • TP-3-PAP immunotoxin was found to effectively kill TP-3+ OHS sarcoma cells.
  • Figure 2 shows the effect of TP-3 MoAb, TP-3- PAP, PAP alone, and an irrelevant immunotoxin construct which binds CD19 on B cells (B43-PAP), on proliferation of human OHS osteosarcoma cells.
  • TP-3 MoAb alone i.e. without PAP toxin
  • HSA human serum albumin
  • TP-3-PAP completely eliminated uptake of 3 H thymidine in the first 4 wells which had OHS cells; OHS did not survive immunotoxin treatment until TP-3-PAP was diluted to
  • Example 4 In vivo administration of TP-3-PAP.
  • mice C57BL/6 mice. Tumors were harvested, minced, and digested by stirring on a magnetic stir plate for 4 hours using 0.4 mg/ml hyaluronidase, 0.05 mg/ml deoxyribonuclease, and 4.0 mg/ml collagenase (Sigma) in RPMI 1640 with 100 u/ml penicillin, 100 ⁇ cg/ml streptomycin, and 2 mM L-glutamine. Cells were filtered through Cell StrainersTM (Falcon, Becton Dickinson), washed three times in Hank's
  • HBSS Balanced Salt Solution
  • MCA106 sarcoma cells (0.4 cc containing 40,000 cells/mouse) into the tail vein of 6-8 week old female C57BL/6 mice.
  • mice with pulmonary metastases were treated with antibody alone or immunotoxin preparations i.p. Numbers of metastases were evaluated by direct counting 14 days after establishment of metastases. After asphyxiation with
  • TP-3 MoAb alone nor irrelevant B43-PAP immunotoxin had any effect on numbers of lung metastases (Table 3).
  • a dose response relationship was examined in a second experiment ( Figure 4). Reduction of pulmonary metastases by TP-3-PAP was dose related and highly significant at doses tested (Table 3). Interestingly, not only were significantly fewer numbers of metastases seen in TP-3-PAP treated mice, but the size of lung metastases in TP-3- PAP treated mice was much smaller than metastases in control mice. Cumulative doses of TP-3-PAP required for significant anti-tumor effects were between 3.75 ⁇ g and 30 ⁇ g/mouse (0.2 to 1.5 mg/kg).

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Toxicology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des agents biothérapeutiques cytotoxiques permettant de traiter certains types de cancers chez l'homme, qui renferment l'anticorps monoclonal murin TP-3 chimiquement conjugué à la protéine antivirale pokeweed (PAP). Elle concerne également une méthode qui utilise lesdits agents biothérapeutiques cytotoxiques pour traiter par voie générale les patients cancéreux. Avec de légères modifications, la méthode de la présente invention devrait pouvoir être appliquée de manière générale à la préparation et à l'utilisation d'autres agents biothérapeutiques cytotoxiques utilisant des dérivés chimiques ou recombinants des anticorps TP-3 ou TP-1 ou de la toxine PAP. L'invention peut être utilisée chez des patients cancéreux qui expriment l'antigène p80 reconnu par les anticorps TP-1/TP-3 soit à la surface des cellules tumorales, soit sur les vaisseaux sanguins tumoraux.
PCT/US1997/014439 1997-08-15 1997-08-15 BIOTHERAPIE DU CANCER PAR CIBLAGE TP-3/p80 WO1999008710A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU39163/97A AU3916397A (en) 1997-08-15 1997-08-15 Biotherapy of cancer by targeting tp-3/p80
PCT/US1997/014439 WO1999008710A1 (fr) 1997-08-15 1997-08-15 BIOTHERAPIE DU CANCER PAR CIBLAGE TP-3/p80

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/014439 WO1999008710A1 (fr) 1997-08-15 1997-08-15 BIOTHERAPIE DU CANCER PAR CIBLAGE TP-3/p80

Publications (1)

Publication Number Publication Date
WO1999008710A1 true WO1999008710A1 (fr) 1999-02-25

Family

ID=22261460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/014439 WO1999008710A1 (fr) 1997-08-15 1997-08-15 BIOTHERAPIE DU CANCER PAR CIBLAGE TP-3/p80

Country Status (2)

Country Link
AU (1) AU3916397A (fr)
WO (1) WO1999008710A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023062A1 (fr) * 1992-05-11 1993-11-25 Immunomedics, Inc. Conjugues therapeutiques de toxines et de medicaments
WO1996021467A1 (fr) * 1995-01-13 1996-07-18 Regents Of The University Of Minnesota BIOTHERAPIE DU CANCER PAR CIBLAGE DE TP-3/p80

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023062A1 (fr) * 1992-05-11 1993-11-25 Immunomedics, Inc. Conjugues therapeutiques de toxines et de medicaments
WO1996021467A1 (fr) * 1995-01-13 1996-07-18 Regents Of The University Of Minnesota BIOTHERAPIE DU CANCER PAR CIBLAGE DE TP-3/p80

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDERSON P.M.: "TP-3 ANTIBODY-POKEWEED ANTIVIRAL PROTEIN (TP-3-PAP) CONJUGATE EFFICIENTYL KILLS OSTEOSARCOMA.", ANTICANCER RESEARCH, vol. 15, no. 5A, 1995, pages 1794 - 1795, XP002063416 *
ANDERSON, PETER M. ET AL: "In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein", CANCER RES. (1995), 55(6), 1321-7 CODEN: CNREA8;ISSN: 0008-5472, 1995, XP002063415 *

Also Published As

Publication number Publication date
AU3916397A (en) 1999-03-08

Similar Documents

Publication Publication Date Title
US4590071A (en) Human melanoma specific immunotoxins
JP3589459B2 (ja) 生物応答調節物質の新規な抗体運送システム
US4664911A (en) Immunotoxin conjugates employing toxin B chain moieties
Sivam et al. Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates
Pirker et al. Characterization of immunotoxins active against ovarian cancer cell lines.
EP0226419B1 (fr) Immunotoxines contre le cancer ovarien humain et méthodes d'utilisation
US6750329B1 (en) Antibody delivery system for biological response modifiers
US6042829A (en) Biotherapy of cancer by targeting TP-3/P80
JP3340127B2 (ja) 異常増殖性疾患措置のための抗体接合体
US5514794A (en) Antibody-drug conjugates
Debinski et al. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent
US5578706A (en) Methods and compositions concerning homogenous immunotoxin preparations
US5728383A (en) Treatment of tumors of the central nervous system with immunotoxins
Gregg et al. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.
Wawrzynczak et al. Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer
US5352447A (en) Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy
WO1999008710A1 (fr) BIOTHERAPIE DU CANCER PAR CIBLAGE TP-3/p80
EP0213881B1 (fr) Application de molécules amphipathiques dans la radiovisualisation et thérapie par des conjugués d'anticorps mono- ou polyclonaux
Flavell et al. Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules
Flavell et al. Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule
Flavell et al. Comparison of the performance of anti‐CD7 and anti‐CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T‐cell acute lymphoblastic leukemia cell line
JPS6069034A (ja) 免疫毒素、免疫毒素を含有する薬剤及び免疫毒素の生体外使用方法
Myers et al. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD 19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule
WO1996005865A1 (fr) Therapie combinee immunotoxine/agent antineoplasique contre le cancer de lignees cellulaires b
Blakey et al. What's new: Immunotoxins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999513112

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载